Clinical trials
Narcolepsy Type 1 clinical trials
Below are recruiting narcolepsy type 1 clinical trials, each written for real people, not researchers. We’re tracking 23 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07871006RecruitingPhase 1/Phase 2
Ofatumumab for difficult-to-treat narcolepsy type 1
This study tests a medication called ofatumumab, which may reduce the immune system attack that causes narcolepsy type 1. It is for people who have not responded to standard treatments and aims to improve symptoms.
Xi'an, ShaanxiAges 10–60 - NCT07727239Recruiting
Brain stimulation trial for people with narcolepsy type 1
This trial tests a non-invasive brain stimulation method called temporal interference to target the hypothalamus. It aims to help reduce excessive daytime sleepiness in people with narcolepsy type 1.
Xi'an, ShaanxiAges 12–60 - NCT07646678RecruitingPhase 2/Phase 3
TAK-360 Extension Study for Narcolepsy or Excessive Sleepiness
This is a follow-up study for people who already completed a TAK-360 trial for narcolepsy (a sleep disorder causing sudden sleep attacks) or idiopathic hypersomnia (excessive daytime sleepiness). Researchers want to see if continuing TAK-360 remains safe and effective for you.
Chula Vista, CaliforniaAges 18–71 - NCT07633301RecruitingPhase 2
TAK-360 Study for Adults With Narcolepsy Type 1
This study tests a new medication called TAK-360 to help adults with narcolepsy type 1 (a condition that causes extreme daytime sleepiness and sudden muscle weakness called cataplexy) feel more alert during the day. The goal is to see if this treatment is safe and effective for managing narcolepsy symptoms.
Redwood City, CaliforniaAges 18–70 - NCT07598708RecruitingPhase 2/Phase 3
Cleminorexton for Narcolepsy: A New Treatment Study
This study tests whether a new medication called cleminorexton helps people with narcolepsy (a condition causing severe daytime sleepiness) sleep better and feel more alert. You would take this medication instead of your current narcolepsy drugs for several months to see if it works.
Birmingham, AlabamaAges 18–70 - NCT07540897RecruitingPhase 3
Testing ALKS 2680 for narcolepsy type 1
This study tests whether a new medication called ALKS 2680 can help people with narcolepsy type 1 stay more awake and alert during the day. Narcolepsy type 1 is a neurological condition where people fall asleep unexpectedly and may experience sudden muscle weakness.
Brandon, FloridaAges 18–70 - NCT07502443RecruitingPhase 3
Study of ALKS 2680 for narcolepsy type 2
This study tests an investigational drug called ALKS 2680 for people with narcolepsy type 2, a condition that causes excessive daytime sleepiness without sudden muscle weakness. The goal is to see if the drug is safe and helps reduce daytime sleepiness.
Cullman, AlabamaAges 18–70 - NCT07455383RecruitingPhase 3
Testing ALKS 2680 for adults with narcolepsy type 1
This study tests a new medication, ALKS 2680, to see if it helps reduce daytime sleepiness and other symptoms in adults with narcolepsy type 1. It may offer a new treatment option for people with this condition.
Cullman, AlabamaAges 18–70 - NCT07096674RecruitingPhase 2
Long-term study of ORX750 for narcolepsy and idiopathic hypersomnia
This trial is for people who have already completed the main CRYSTAL-1 study of ORX750. It tests the long-term safety and effects of the drug, so you can continue treatment if it was helping you.
Auburn, AlabamaAges 18–65 - NCT01793168Recruiting
Rare disease registry and history study
This study keeps a registry (a structured list) of people with rare diseases and may also track how the condition changes over time. It can help researchers better understand rare illnesses and find gaps in care, which may improve future treatments.
Sioux Falls, South DakotaAges Any age - NCT07006233Recruiting
Dietary change study for narcolepsy and hypersomnia
This study tests whether changing your diet to include more animal protein and fat (like a low-carb diet) can improve symptoms of narcolepsy or idiopathic hypersomnia. You'll need to check your ketone levels at home and be willing to make lasting dietary changes.
Macquarie Park, New South WalesAges 18 years+ - NCT06809803RecruitingPhase 2
Extended-release sodium oxybate for children with narcolepsy
This trial tests an extended-release medicine (sodium oxybate) to see if it helps children with narcolepsy type 1 feel less sleepy during the day. It is only for children who are seen at the Stanford Sleep Clinic and have a clear diagnosis.
Redwood City, CaliforniaAges 7–17 - NCT06767683RecruitingPhase 2/Phase 3
Long-term study of ALKS 2680 for narcolepsy and idiopathic hypersomnia
This study continues treatment with the investigational drug ALKS 2680 for people who have already completed a previous ALKS 2680 study for narcolepsy or idiopathic hypersomnia. It aims to see how safe and effective the drug is over a longer period.
Cullman, AlabamaAges 18–70 - NCT06752668RecruitingPhase 2
Testing ORX750 for narcolepsy and idiopathic hypersomnia
This trial tests an experimental drug called ORX750 for people with narcolepsy or idiopathic hypersomnia. You would need to stop your current sleepiness medicines to see if ORX750 helps reduce daytime sleepiness.
Auburn, AlabamaAges 18–65 - NCT06484348Recruiting
How food affects sleepiness in narcolepsy and hypersomnia
This study explores how what you eat affects your sleepiness and nighttime sleep quality. Researchers want to learn more about these links in people with narcolepsy type 1 or idiopathic hypersomnia.
Clermont-FerrandAges 18–65 - NCT06383806Recruiting
Reducing nightmares in adults with narcolepsy
This study tests a new behavioral treatment to reduce nightmares in adults with narcolepsy. It aims to help you sleep better and feel more rested.
Salt Lake City, UtahAges 18 years+ - NCT06292598Recruiting
Gut bacteria and sleep disorder study
This study compares gut bacteria and substances from the gut in people with type 1 narcolepsy versus those without. It aims to understand how gut health might be linked to this sleep disorder.
Nîmes, GardAges 10 years+ - NCT05773872Recruiting
Testing social understanding in narcolepsy and hypersomnia
This study compares “social cognition” (how people recognize and understand others’ thoughts and feelings) in adults with narcolepsy or idiopathic hypersomnia. It may help researchers better understand how these conditions can affect everyday social interactions.
AmiensAges 18 years+ - NCT07584434RecruitingPhase 1
Safety and Dosage Study of VX-433 in Healthy People
This is a first-in-human study testing a new drug called VX-433 to see how safe it is and how the body handles it. Vertex Pharmaceuticals is running this early-stage trial to understand the right dosage and side effects in healthy volunteers.
Salt Lake City, UtahAges 18–55 - NCT06457945Recruiting
Mind-wandering and daydreaming in narcolepsy and hypersomnia
This study looks at whether people with narcolepsy or idiopathic hypersomnia have different patterns of daydreaming and mind-wandering compared to others with sleepiness but no clear diagnosis. It helps understand how certain brain states during sleep might affect waking thoughts.
LyonAges 18–65 - NCT07365566Recruiting
Pain and sleep behavior disorder study
This study looks at pain in people with a sleep condition called idiopathic REM sleep behavior disorder (iRBD), where people act out their dreams. It also includes a group of people with narcolepsy who have similar sleep issues. The goal is to understand how pain relates to these conditions.
ToulouseAges 18 years+ - NCT05816382RecruitingPhase 2/Phase 3
Testing TAK-861 for narcolepsy type 1 sleepiness
This Phase 2/3 study tests TAK-861 in people with narcolepsy type 1 (NT1) who already completed an earlier TAK-861 trial. The goal is to see if the medicine remains safe and effective for ongoing central (brain-related) sleepiness problems.
Birmingham, AlabamaAges 16–70 - NCT06952699RecruitingPhase 2
TAK-360 for narcolepsy type 2
This study tests a new medicine called TAK-360 for people with narcolepsy type 2 (narcolepsy without cataplexy). It aims to see if the drug safely reduces daytime sleepiness.
Auburn, AlabamaAges 18–70
Hear when a new Narcolepsy Type 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Narcolepsy Type 1 trials by city
Studies with a site in or near these metro areas.
Narcolepsy Type 1 trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for narcolepsy type 1?
- Yes. Clin2 currently lists 23 recruiting narcolepsy type 1 studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a narcolepsy type 1 trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a narcolepsy type 1 trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.